Dokument: Insulin-like growth factor binding protein 2 (IGFBP-2) as prognostic parameter in infarct-related cardiogenic shock
| Titel: | Insulin-like growth factor binding protein 2 (IGFBP-2) as prognostic parameter in infarct-related cardiogenic shock | |||||||
| URL für Lesezeichen: | https://docserv.uni-duesseldorf.de/servlets/DocumentServlet?id=71121 | |||||||
| URN (NBN): | urn:nbn:de:hbz:061-20251027-103614-3 | |||||||
| Kollektion: | Publikationen | |||||||
| Sprache: | Englisch | |||||||
| Dokumententyp: | Wissenschaftliche Texte » Artikel, Aufsatz | |||||||
| Medientyp: | Text | |||||||
| Autoren: | Masyuk, Maryna [Autor] Kelm, Malte [Autor] Schemmelmann, Mara [Autor] Gerdes, Norbert [Autor] Jung, Christian [Autor] Wernly, Bernhard [Autor] Freund, Anne [Autor] Pöss, Janine [Autor] Desch, Steffen [Autor] Schneider, Steffen [Autor] | |||||||
| Dateien: |
| |||||||
| Stichwörter: | IGFBP-2 , Biomarker , Acute myocardial infarction , Cardiogenic shock | |||||||
| Beschreibung: | Background
Cardiogenic shock (CS) caused by acute myocardial infarction (AMI) is a critical condition with high mortality rate. Insulin-like growth factor binding protein 2 (IGFBP-2) is dysregulated in cardiovascular diseases. The purpose of the present study was to investigate the prognostic value of IGFBP-2 in patients with AMI-CS. Methods This study is a post-hoc analysis of the randomized multicentre CULPRIT-SHOCK trial. IGFBP-2 levels were measured in serum samples from 423 patients using commercially available enzyme-linked immunosorbent assay (ELISA) kits. Associations of IGFBP-2 with 30-day and one-year mortality were investigated. Results Median IGFBP-2 concentration was 415 ng/ml (IQR 274–699 ng/ml). Patients with IGFBP-2 ≥ median demonstrated higher 30-day (54 % vs. 37 %; p < 0.001) and one-year mortality (60 % vs. 42 %; p < 0.001) compared to the < median group. Higher IGFBP-2 concentrations were associated with increased 30-day and one-year mortality, irrespective of it being analysed as continuous or categorical variable (per 100 ng/ml IGFBP-2, hazard ratio (HR) 1.06; 95 % confidence interval (CI) 1.04–1.09; p < 0.001, respectively; IGFBP-2 ≥ vs. < median, HR 1.70, 95 % CI 1.23–2.35, p = 0.001 and HR 1.72, 95 %CI 1.27–2.33, p < 0.001). Furthermore, IGFBP-2 ≥ median was associated with increased 30-day (HR 1.70; 95 %CI 1.23–2.35; p = 0.001) and one-year mortality (HR 1.72; 95 %CI 1.27–2.33; p < 0.001), even after adjustment for established prognostic factors. Conclusions In AMI-CS, elevated levels of IGFBP-2 were associated with higher mortality at 30 days and one year after admission. IGFBP-2 represents a promising prognostic biomarker and could add value to risk stratification in this high-risk patient cohort, potentially informing early clinical decision-making. | |||||||
| Rechtliche Vermerke: | Originalveröffentlichung:
Masyuk, M., Wernly, B., Kelm, M., Freund, A., Pöss, J., Desch, S., Schneider, S., Akin, I., Fürnau, G., Ceglarek, U., Schemmelmann, M., Isermann, B., Gerdes, N., Schrage, B., Zeymer, U., Büttner, P., Thiele, H., & Jung, C. (2025). Insulin-like growth factor binding protein 2 (IGFBP-2) as prognostic parameter in infarct-related cardiogenic shock. International Journal of Cardiology, 443, Article 133961. https://doi.org/10.1016/j.ijcard.2025.133961 | |||||||
| Lizenz: |  Dieses Werk ist lizenziert unter einer Creative Commons Namensnennung 4.0 International Lizenz | |||||||
| Fachbereich / Einrichtung: | Medizinische Fakultät | |||||||
| Dokument erstellt am: | 27.10.2025 | |||||||
| Dateien geändert am: | 27.10.2025 |
